Precision Before Prescription™

We’ve developed the world’s first genetic test that screens all 5,886 HER2+ TK mutations to determine whether the most commonly prescribed HER2 drugs (and our biosimilar) will actually bind to your HER2 gene — or not.

Why Choose Us?

Unmatched Testing

We’re the first to test every known and newly discovered mutation in HER2+ cancers — not just the top 10.

Patient-First Promise

We pay for the genetic test. Even if our drug isn’t right for you, we’ll tell you. That’s ethics.

Data-Driven Confidence

We’ve tested over 20,000 biosimilar variants in the lab and selected the best-performing one — before clinical trials.

Rapid Drug Development

Thanks to new UK biosimilar regulations, we can bring safe, effective drugs to market in under 3 years, for under $10 million.

Trust through Transparency

When our biosimilar is one of the few drugs that might work for you, you'll know we earned that place.

The Science Behind Our Breakthrough

Let’s Talk

Whether you’re a physician, patient, investor, or partner — if you’re ready to change the future of medicine, we want to hear from you.

FAQ

Why aren't other drug companies doing this?
Most companies focus on profit and speed. We focus on saving lives and building long-term trust.
Is this test available now?
We’re currently rolling out our HER2+ test for select clinics and trials. Full patient access is expected soon.
What does it cost?
The genetic test is fully covered by us — no charge to the patient.
Will my doctor understand how to use the test results?
Absolutely. We provide a clear report showing which HER2 drugs are likely to work or not, with supporting data.